Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2017

01-11-2017 | Letter to the Editor

Letter to the editor: In response to “influence of clinical, societal, and treatment variables on racial difference in ER-/PR- breast cancer survival” by Roseland ME, Schwartz K, Ruterbusch JJ, Lamerato L, Krajenta R, Booza J, Simon MS

Author: Constance Hilliard

Published in: Breast Cancer Research and Treatment | Issue 1/2017

Login to get access

Excerpt

While I agree with this article that social determinants play an important role in explaining the higher mortality of Black women with triple-negative breast cancer, my research as an evolutionary historian, points to epigenetics as being an even more pivotal factor. The central actor is the TRPV6 gene, which has an “ancestral” variant carried by Africans and a “derived” haplotype found in Europeans and Asians. …
Literature
1.
2.
Fu S, Hirte H, Welch S et al (2017) First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. Invest New Drugs 35:324CrossRefPubMedPubMedCentral
3.
Jiang Y, Gou H, Zhu J, Tian S, Yu L (2016) Lidocaine inhibits the invasion and migration of TRPV6-expressing cancer cells by TRPV6 downregulation. Oncol Lett 12(2):1164–1170PubMedPubMedCentral
Metadata
Title
Letter to the editor: In response to “influence of clinical, societal, and treatment variables on racial difference in ER-/PR- breast cancer survival” by Roseland ME, Schwartz K, Ruterbusch JJ, Lamerato L, Krajenta R, Booza J, Simon MS
Author
Constance Hilliard
Publication date
01-11-2017
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4360-z

Other articles of this Issue 1/2017

Breast Cancer Research and Treatment 1/2017 Go to the issue

Preclinical study

Postlactational involution biomarkers plasminogen and phospho-STAT3 are linked with active age-related lobular involution

Epidemiology

Diagnosis and treatment delays among elderly breast cancer patients with pre-existing mental illness

Epidemiology

Adiposity during early adulthood, changes in adiposity during adulthood, attained adiposity, and mammographic density among premenopausal women

Erratum

Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial

Epidemiology

Fatty liver decreases the risk of liver metastasis in patients with breast cancer: a two-center cohort study

Clinical trial

Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits